Johnson & Johnson to Begin Human Trials of Covid-19 Vaccine by September -- Update
March 30 2020 - 9:49AM
Dow Jones News
By Matt Grossman
Johnson & Johnson said Monday that it had made progress on a
vaccine to prevent Covid-19 and that the product could be ready in
early 2021.
The New Brunswick, N.J., company selected a lead candidate for
the vaccine from the constructs it had been working on, and said
human trials would begin by September at the latest.
J&J said it could get approval under an emergency-use
authorization to make the vaccine widely available early next year.
The company said it has also chosen two back-up constructs in case
the lead candidate falters.
The company said the vaccine, if successful, would be affordable
and would be sold on a not-for-profit basis.
Johnson & Johnson is one of many companies at work on a
vaccine for the disease, which has become a global health crisis.
Moderna Inc. has begun human trials for a vaccine using a novel
approach that relies on the virus's messenger RNA, a type of
genetic material. Sanofi, a French biotech company, has begun work
on a similar approach.
Johnson & Johnson said it would try to scale its global
manufacturing capabilities to make more than 1 billion doses of a
Covid-19 vaccine by the end of next year. It said it is also
working with the Biomedical Advanced Research and Development
Authority, a part of the Department of Health and Human Services,
to expand its research into a treatment for Covid-19.
(END) Dow Jones Newswires
March 30, 2020 09:34 ET (13:34 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Sep 2023 to Sep 2024